IRESSA 250 mg/1

IRESSA 250 mg tablets contain gefitinib, a medication used to treat certain types of cancer. This oral medication is designed for targeted therapy and is manufactured by AstraZeneca Pharmaceuticals LP.

IRESSA 250 mg tablets are primarily used in the treatment of specific types of non-small cell lung cancer. Gefitinib is a tyrosine kinase inhibitor that targets certain proteins involved in cancer cell growth. This medication is often prescribed for patients with specific genetic mutations that make their cancer cells dependent on these proteins for growth and survival. It is important to consult with a healthcare provider to determine if IRESSA 250 mg tablets are suitable for your condition.

Common effects of IRESSA 250 mg tablets may include skin rash, diarrhea, and nausea. Some users may also experience dry skin, loss of appetite, or changes in hair texture. These effects can vary in intensity and duration. If you experience severe or persistent side effects, it is advisable to seek medical attention.

IRESSA 250 mg tablets should be handled with care and stored as directed. It is important to follow the prescribed dosage and administration instructions provided by your healthcare provider. This medication may interact with other drugs, so it is crucial to inform your healthcare provider about all medications you are taking. Pregnant or breastfeeding women should consult their healthcare provider before using IRESSA 250 mg tablets.

IRESSA 250 mg tablets may interact with certain medications, including those that are metabolized by the liver enzyme CYP3A4. This can affect the effectiveness of gefitinib or other drugs. It is important to avoid grapefruit and grapefruit juice, as they can also interact with gefitinib. Always inform your healthcare provider about all medications, supplements, and herbal products you are taking to minimize the risk of interactions.